Test page
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum
Rising to the challenge of childhood cancer requires a fundamental change in the way children’s and young people’s cancer drugs are discovered, developed and brought to market. C-Further is committed to driving that change.
David Jenkinson
Head of Childhood Cancer Translational Challenge, LifeArc
News and events
We are creating a consortium united in the unwavering belief that we can challenge conventional approaches and accelerate translation of promising ideas into new therapies for children and young people affected by cancer.
Stay up to date on our latest news, events and research.
From Chemo to CAR-T: A mum’s call for Child-First Drug Design
Courtney Addison on her son Cayden's cancer journey and the need for more targeted paediatric cancer treatments in an interview with C-Further.
Annual review 2024-2025
C-Further reports on our progress and activities since launch in our annual review of 2024-2025
C-Further announces major partnership with GOSH Charity to drive innovation in childhood cancer treatment
GOSH Charity joins Cancer Research Horizons and LifeArc as a core partner of C-Further.
Voices for paediatric progress: Iris Valtingojer
Iris Valtingojer, PhD, shares her vision for transforming childhood cancer R&D through innovation, equity, and collaboration.
Our approach
We'll bring together researchers, clinicians, scientists in drug discovery and development, partners and impact investors who share our commitment to children and young people. By working in collaboration and removing barriers to progress, we can create a model to advance innovative treatments for young patients.
We’re also committed to involving and engaging with people affected by children's and young people's cancers to guide, influence and shape the work of the consortium.
Highlights from our inaugural round
Ut posuere, nunc vitae pulvinar imperdiet, sem lectus maximus dolor, sit amet ornare ante quam in ex. Aenean eget turpis nec lectus suscipit sagittis a vel erat.
9
Modalities
More than
10
New indications
Applications from
9
Different countries
Our first round in numbers
We received a remarkable response, with applications from both industry and academia.
9
modalities
Over
10
indications
Applications from
12
countries
Upcoming deadline: 1 September 2025
We welcome expressions of interest at any time, but to be reviewed in this round, they must be submitted before the closing date at 23:59 GMT. Early submissions are encouraged.
Children's Cancer Therapeutics Consortium
Founding partners
